openPR Logo
Press release

Atrial Fibrillation - Pipeline Review, H2 2017

10-25-2017 03:21 PM CET | Health & Medicine

Press release from: ReportsWorldwide

Atrial Fibrillation - Pipeline Review, H2 2017

Atrial Fibrillation - Pipeline Review, H2 2017

ReportsWorldwide has announced the addition of a new report title Atrial Fibrillation - Pipeline Review, H2 2017 to its growing collection of premium market research reports.

Summary
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Atrial Fibrillation - Pipeline Review, H2 2017, provides an overview of the Atrial Fibrillation (Cardiovascular) pipeline landscape.

Atrial fibrillation is an irregular and often rapid heart rate that commonly causes poor blood flow to the body. Symptoms include decreased blood pressure, weakness, lightheadedness, confusion and chest pain. The predisposing factors include age, heart disease, high blood pressure, family history and drinking alcohol. Treatments for atrial fibrillation may include medications and surgery.

To Enquire about this Report please visit @ https://www.reportsworldwide.com/enquiry?report_id=41668

Report Highlights
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Atrial Fibrillation - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Atrial Fibrillation (Cardiovascular), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Atrial Fibrillation (Cardiovascular) pipeline guide also reviews of key players involved in therapeutic development for Atrial Fibrillation and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 1, 3, 2, 8 and 2 respectively. Similarly, the Universities portfolio in Phase I, Preclinical and Discovery stages comprises 1, 2 and 1 molecules, respectively.

Atrial Fibrillation (Cardiovascular) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

To view a detailed description and Table of Contents please visit: https://www.reportsworldwide.com/report/atrial-fibrillation-pipeline-review-h2-2017

Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Atrial Fibrillation (Cardiovascular).
- The pipeline guide reviews pipeline therapeutics for Atrial Fibrillation (Cardiovascular) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Atrial Fibrillation (Cardiovascular) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Atrial Fibrillation (Cardiovascular) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Atrial Fibrillation (Cardiovascular)

Reasons to buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Atrial Fibrillation (Cardiovascular).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Atrial Fibrillation (Cardiovascular) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

ReportsWorldwide.com is a leading provider of global market intelligence reports and services. With research reports from top publishers, consulting and advisory firms, ReportsWorldwide.com offers instant online access to a growing database of expert insights on global industries, companies, products, geographies and trends.

Press Contact:
Abigail Crasto
Senior Vice President
101, Arch Street
Boston,
MA 02110
US
Phone +1 (617) 398-1947

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Atrial Fibrillation - Pipeline Review, H2 2017 here

News-ID: 786025 • Views: 208

More Releases from ReportsWorldwide

World Deep Brain Stimulation Market Top Segments, Key Players Revenue, Growth Ra …
The World Deep Brain Stimulation Market is estimated to represent a global market of USD 751.8 million by 2017 with growth rate of 18.2%. Deep brain stimulation (DBS) procedure is primarily used for the treatment of neuropsychiatric disorders such as mood disorder, dementia, anxiety and others. The procedure involve the use of neurotransmitter (brain pacemaker) that enables to transmit electric impulses to the specific target of brain cells. Increasing incidence
New report explores the Gene Editing Market : Ushering The Next Breakthrough in …
Boston, MA ReportsWorldwide has announced the addition of a new report title Gene Editing The Next Breakthrough in Regenerative Medicine to its growing collection of premium market research reports. Genome editing is a type of genetic engineering in which DNA is replaced, inserted or deleted in a living organism's ggenome using engineered molecular scissors. Believed to be one of the great biotechnology breakthroughs, gene editing is a powerful tool in pharmaceutical research that
Global In-Building Wireless BTSController-based Small Cells Market Analysis and …
Boston, MA ReportsWorldwide has announced the addition of a new report title Global In-Building Wireless BTSController-based Small Cells Market Analysis and Forecast, 2017-2021 to its growing collection of premium market research reports. This report covers the leading in-building wireless enterprise BTS/controller-based small cells network equipment manufacturers: • CommScope/Airvana • Comba Telecom • Ericsson • Huawei Technologies • Nokia • SpiderCloud • ZTE Corporation This report covers the global market share for 2016 shipments as well as a forecast for 2017-2021. To view a detailed description and Table of
UDAY’s Impact and Compatibility State wise indexing of Integrated Power Supply …
Boston, MA ReportsWorldwide has announced the addition of a new report title UDAY’s Impact and Compatibility State wise indexing of Integrated Power Supply Chain in India – 2017 to its growing collection of premium market research reports. UDAY scheme was touted as the next paladin to bail out the struggling Discoms, in order to turn them green in a time horizon of 3-4 years from 2015/16. Though was optional for the

All 5 Releases


More Releases for Atrial

Atrial Fibrillation Market
Atrial Fibrillation Market is predicted to grow at a double digit CAGR over the forecast period (2017 to 2023). Atrial fibrillation, also denoted as AF, is an irregular or fast heart rhythm. It raises the dangers of chest pain, heart strokes, congestive heart failure, or cardiac discomfort. The typical indications of AF are dizziness, confusion, fainting, or tiredness. Therapeutic advancements and the burgeoning aged populace also drive the industry. Supportive clinical
Atrial Fibrillation Stroke Treatment Market Segmentation By Atrial Fibrillation …
The arrhythmia problem occurs due to irregular heartbeats which can cause atrial fibrillation stoke. The irregular manner (increase pattern or lower pattern of heart beats) of heart beating pattern can cause atrial fibrillation stroke. The atrial fibrillation stroke causes major problem of heart and increase heart related problem. The patient which are suffering from atrial fibrillation effect two chamber of heart and atria present below the heart will lead to
Atrial Fibrillation Market Opportunity Analysis, 2018-2026
Atrial fibrillation, also known as A-fib or AF, is an irregular heartbeat exemplified by rapid and abnormal beating of the heart. Most episodes of atrial fibrillation have no symptoms or fewer symptoms such as intermittent heart palpitations, lightheadedness, fainting, chest pain, and shortness of breath. Atrial fibrillation is linked with an elevated risk of heart failure, stroke, and dementia. The disease is a kind of supraventricular tachycardia. Risk factors associated
Atrial Septal Defect Market Future Opportunities2017 - 2025
Global Atrial Septal Defect Market: Outlook Atrial septal defect is one of the most common congenital cardiac diseases and usually affects women more than men. It is characterized by a hole or defect in the interatrial septum that separates the heart’s two upper chambers, i.e., atria. The opening in the septum usually closes when the baby is born, but in few cases if the opening does not close, the hole
Atrial Flutter Market Progresses For Huge Profits During 2025
Atrial flutter is abnormal heart rhythm. It is characterized by atrial rates of 240 to 400 beats per minute and blockage in atrioventricular node. Atrioventricular node controls the heart rate and is one of the major elements in the cardiac conduction system. Atrial flutter leads to irregular electrical impulse of the heart resulting in disorganized contraction in parts of heart and disability to pump required amount of blood. The common
Atrial Septal Defect Market Research Report Forecast 2016-2024
Global Atrial Septal Defect Market: Outlook Atrial septal defect is one of the most common congenital cardiac diseases and usually affects women more than men. It is characterized by a hole or defect in the interatrial septum that separates the heart’s two upper chambers, i.e., atria. The opening in the septum usually closes when the baby is born, but in few cases if the opening does not close, the hole